¼¿ï´ëÇб³ÀÇ ÀÌÁö¿ì ±³¼ö´Â Áö³ 18³â°£ Ä¡¸Å Ä¡·áÁ¦ ½Å¾à°³¹ß ¿¬±¸¿¡ ÁýÁßÇØ¿ÔÀ¸¸ç, ¿¬±¸¾÷ÀûÀ¸·Î ¾à 130¿© ÆíÀÇ ³í¹®À» ±¹Á¦Àû ÇмúÁö¿¡ ¹ßÇ¥Çß´Ù. Àü ¼¼°èÀûÀ¸·Î Ä¡¸ÅÄ¡·áÁ¦·Î ÀÓ»óÁßÀÎ ÈÇÕ¹°Àº ¸î °³ µÇÁö ¾ÊÀ¸¸ç ÀÌÁö¿ì ±³¼ö°¡ ¿¬±¸ÇÏ°í ÀÖ´Â µ¶Ã¢ÀûÀÎ °³¹ß ÈÇÕ¹°ÀÌ ¼º°ø µÉ °æ¿ì Ä¡¸Å¸¦ Á¤º¹ÇÒ ¼ö ÀÖ´Â ¹ßÆÇÀ» ¸¶·ÃÇÏ°Ô µÈ´Ù.
´ÏÄݶó Æ®¶óºñ¿¡¼Ò ¹Ú»ç´Â ÇöÀç NTC»çÀÇ »çÀåÀ¸·Î ¾àÇлçÀÇ ÇÐÀ§¸¦ ÃëµæÇÏ°í ¹ýÇйڻçÇÐÀ§¸¦ ¹ÞÀ½°ú µ¿½Ã¿¡ MBA¸¦ ÃëµæÇÑ ´Ù±¹ÀûÁ¦¾à»çÀÇ ±¹Á¦¸¶ÄÉÆà Àü¹®°¡ÀÌ´Ù. ¶ÇÇÑ ÇØ¿Ü Á¦¾àȸ»çÀÇ »ç¿ÜÀÌ»ç·Î ÁÖ¿ä Á¤Ã¥ÀûÀÎ ¹®Á¦¿¡ ´ëÇÑ ÀÚ¹®¿ª ƯÈ÷ ¸Å³â °³ÃֵǴ CPhI(ÈÇпø·á ¹× Á¦¾à¿ø·á) ¼¼°èÃÑȸ¿¡¼ ±âÁ¶¿¬¼³À» µµ¸Ã¾Æ ÇÏ´Â µî ±¹Á¦È¸ÀÇ¿¡¼ÀÇ ¸í¼ºÀ» ½×°í ÀÖ´Ù.
¼ÛÀ½ ÀÇ․¾àÇлóÀº µ¿¼ºÁ¦¾àÀ» ¼³¸³ÇÑ ¼ÛÀ½ À̼±±ÔȸÀåÀº 'ºÀ»çÇÏ´Â Àλý'À̶ó´Â öÇÐÀ¸·Î ±â¾÷ÀÌÀ±À» »çȸ¿¡ ȯ¿ø½ÃÅ°°íÀÚ ÀÌ »óÀ» Á¦Á¤ÇÏ¿© 1998³â Á¦1ȸ·Î ½ÃÀÛ, ¾à¾÷°èÀÇ ¸¹Àº °ü½É ¼Ó¿¡¼ Á¦¾àȸ»ç ´Üµ¶À¸·Î ½Ã»ó½ÄÀ» ÁøÇàÇÏ¿© ¿ÔÀ¸¸ç, ±¹³»»Ó¸¸ ¾Æ´Ï¶ó ¼¼°èÀûÀÎ ¿¬±¸¼º°ú¸¦ ´ë»óÀ¸·Î ½É»çÇÏ¿© ½Ã»óÇÏ°í ÀÖ´Ù.
ÀÌ ³¯ µ¿¼ºÁ¦¾àÀº ¼ÛÀ½ÇмúÀç´ÜÀ» ÅëÇØ ÃÊ·Ï¿ì»ê ¾î¸°ÀÌÀç´ÜÀ¸·ÎºÎÅÍ Ãßõ ¹ÞÀº û¼Ò³â 16¸í¿¡°Ô ÀåÇбÝÀ» Àü´ÞÇÏ´Â Çà»çµµ ÇÔ²² ÁøÇàÇß´Ù.
¡à ¼º ¸í : ÀÌ Áö ¿ì (ì° òª éë)
[ÇзÂ]
1979.03 – 1983.02 : ¼¿ï´ëÇб³ ¾àÇдëÇÐ Á¦¾àÇаú Á¹¾÷
1983.03 – 1985.02 : ¼¿ï´ëÇб³ ¾àÇдëÇпø ¼®»ç
1986.08 – 1991.01 : ´º¿åÁÖ¸³´ë ¾àÇйڻç (ÀǾàÈÇÐÀü°ø)
State University of New York at Buffalo
Department of Medicinal Chemistry
[°æ·Â]
±³À°
1991.01 – 1995.08 : National Cancer Institute, NIH ¿¬±¸¿ø
1995.09 – 1999.09 : ¼¿ï´ëÇб³ ¾àÇдëÇÐ Á¶±³¼ö
1999.10 – 2005.03 : ¼¿ï´ëÇб³ ¾àÇдëÇÐ ºÎ±³¼ö
2005.04 – ÇöÀç : ¼¿ï´ëÇб³ ¾àÇдëÇÐ ±³¼ö
º¸Á÷
2007.07 - 2009.07 : ¼¿ï´ëÇб³ ¾àÇдëÇÐ ¿¬±¸/Çлý ºÎÇÐÀå
2009.08 - 2013.07 : ¼¿ï´ëÇб³ ¾àÇдëÇÐ Á¾ÇÕ¾àÇבּ¸¼Ò ¼ÒÀå
ÇÐȸ
1999. 01 - 2000. 12 : ´ëÇѾàÇÐȸ ÇмúÀ§¿ø
2001. 01 - 2002. 12 : ´ëÇѾàÇÐȸ Archives ÆíÁýÀ§¿ø
2003. 07 - ÇöÀç : Editorial Advisory Board, Letter in Drug Design & Discovery
2013. 03 - ÇöÀç : Editorial Advisory Board, Journal of Medicinal Chemistry
»ê¾÷
2002.01 – 2005.12 : ¢ß µðÁöÅйÙÀÌ¿ÀÅØ (ÇöÄÚ½º´Ú »óÀå»ç ¸ÞµðÇÁ·Ð) ´ëÇ¥ÀÌ»ç
[¼ö»ó]
2004. 12. 01: º¸°Çº¹ÁöºÎ ¿ì¼ö¿¬±¸ÀÚ»ó ¼ö»ó
2005. 04. 14: ƯÇã±â¼ú»ó (¼¼Á¾´ë¿Õ»ó)
2006. 10. 19: º¥Ã³»ê¾÷ÁøÈï»ó (±¹¹«ÃѸ®»ó)
2010. 05. 25: Á¦32ȸ »êÇÐÇùµ¿»ó (¿ì¼ö»ó)
2010. 12. 09: 2010³â ´ëÇѹα¹ 10´ë ½Å±â¼ú»ó
[¿¬±¸]
SCI ±¹Á¦Àú³Î ÃÑ 130¿©Æí
ƯÇã 30¿©Æí
- TRPV1 ligand°è ½Åº´º´Áõ¼º ÅëÁõ ÁøÅëÁ¦ °³¹ß¿¬±¸
- Beta–Amyloid »ý¼º¾ïÁ¦ ±âÀüÀÇ Ä¡¸ÅÄ¡·áÁ¦ °³¹ß¿¬±¸
- RAGE antagonist ±âÀüÀÇ Ä¡¸ÅÄ¡·áÁ¦ °³¹ß¿¬±¸
- Glutamine Cyclase ÀúÇØÁ¦ ±âÀüÀÇ Ä¡¸ÅÄ¡·áÁ¦ °³¹ß¿¬±¸
- Neuronal Stem cell ºÐȱâÀüÀÇ Ä¡¸ÅÄ¡·áÁ¦ °³¹ß¿¬±¸
- Protein Kinase C Ligand°è Ç×¾ÏÁ¦ °³¹ß¿¬±¸
- Aminoacyl-tRNA Synthetase ÀúÇØÁ¦ ±âÀüÀÇ Ç×¾ÏÁ¦/Ç×»ýÁ¦ °³¹ß¿¬±¸
[±â¼úÀÌÀü ½ÇÀû]
- 2004. 02 : TRPV1 antagonist ÁøÅëÁ¦, 1610¾ï¿¡ Schwartz»ç¿¡ ±â¼úÀÌÀü
- 2004. 05 : TRPV1 antagonist ÁøÅëÁ¦, 10¾ï¿¡ ¢ßÅÂÆò¾ç¿¡ ±â¼úÀÌÀü
- 2006. 03 : TRPV1 antagonist ÁøÅëÁ¦, 480¾ï¿¡ Grunenthal»ç¿¡ ±â¼úÀÌÀü
- 2007. 04 : ÀÌÁß±âÀü ÁøÅëÁ¦, 116¾ï¿¡ Grunenthal»ç ±â¼úÀÌÀü
- 2008. 11 : Beta–Amyloid »ý¼º¾ïÁ¦ ±âÀüÀÇ Ä¡¸ÅÄ¡·áÁ¦, ´ë¿õÁ¦¾à°ú °øµ¿°³¹ß
- 2010. 02 : RAGE antagonist Ä¡¸ÅÄ¡·áÁ¦, 3260¾ï¿¡ Roche»ç¿¡ ±â¼úÀÌÀü
[´ëÇ¥³í¹®]
Yoon, H. J.; Kong, S-Y.; Park, M-H.; Cho, Y.; Kim, S-E.; Shin, J-Y.; S.; Lee, J.; Farhanullah, Kim, H-J.; Lee, J.;
Aminopropyl carbazo;e analogues as potent enhancers of neurogenesis
Bioorgarnic & Medicinal Chemistry 2013, 21(22), 7165-7174.
Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-l-yl)propyl thiourea template
Bioorgarnic & Medicinal Chemistry 2013, 21(13), 3821-3830.
Ligand-Based Design, Synthesis, and Biological Evaluation df 2-Aminopyrimidines, a Novel Series of Receptor for Advanced Glycation End Products (RAGE) Inhibitors.
Journal of Medicinal Chemistry 2012, 55(21), 9120-9135.
2-(3-Fluoro-4-methylsulfonylaminophenyl) Propanamides as Potent Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists: Structure Activity Relationships of 2-Amino Derivatives in the N-(6-trifluoromethyl-pyridin-3-ylmethyl) C-region
Journal of Medicinal Chemistry 2012, 55(19), 8392-8408.
Stereospecific High-affinity TRPV1 Antagonists: Chiral N-(2-Benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide Analogues
Journal of Medicinal Chemistry 2008, 51(1), 57-67.
[´ëǥƯÇã(Ä¡¸Å°ü·Ã]
1. º£Å¸¾Æ¹Ð·ÎÀ̵å ÀÀÁý¾ïÁ¦Á¦ (´ë¿õÁ¦¾à °øµ¿°³¹ß)
- ´ëÇѹα¹ ƯÇãµî·Ï : 10-0858357
º¥Á¶Ç»¶õ°è À¯µµÃ¼ ÈÇÕ¹°À» À¯È¿¼ººÐÀ¸·Î ÇÔÀ¯ÇÏ´Â ÀÎÁö±â´É Àå¾ÖÀÇ ¿¹¹æ ¹×
Ä¡·á¿ë Á¶¼º¹°
- PCT: WO 2008/041826
Novel benzofuran type derivatives, A composition comprising the same for
treating or preventing cognitive dysfunction and the use thereof.
- US patent: US 8,507,553 $ US 8,455,542
Benzofuran type derivatives, A composition comprising the same for treating
or preventing cognitive dysfunction and the use thereof.
2. RAGE ±æÇ×Á¦(Roche °øµ¿°³¹ß)
- ´ëÇѹα¹ ƯÇãÃâ¿ø : 10-2012-0043953
½Å±ÔÇÑ º¥Á¶¿Á»çÁ¹°è À¯µµÃ¼ ¶Ç´Â ÀÌÀÇ ¾àÇÐÀûÀ¸·Î Çã¿ë°¡´ÉÇÑ ¿°, ÀÌÀÇ Á¦Á¶¹æ¹ý ¹× À̸¦ Æ÷ÇÔÇÏ´Â RAGE ¼ö¿ëü °ü·Ã ÁúȯÀÇ ¿¹¹æ ¶Ç´Â Ä¡·á¿ë ¾àÇÐÀû Á¶¼º¹°
- Roche »ç ±â¼úÀÌÀü ±â»ç
¡à ¼º ¸í : ´ÏÄݶó Æ®¶óºñ¿¡¼Ò
[°æ·Â]
▪ 1980 ´Ù±¹Àû ±â¾÷ Henkel ¸¶ÄÉÆúΠ±Ù¹«
▪ 1985 Á¦¾àȸ»ç ±Ù¹«: licensing in & out ¹× international marketing & sales
▪ 1997 NTC S.r.l. ¼³¸³
▪ ±¹Á¦ÇÐȸ ¿¬ÀÚ·Î È°µ¿
- CPhl conferences 2013, Poland
: Innovation strategies for generic drug companies - moving into super generics
- Generics&Biosimilars Summit 2012, Istanbul
: Cost reduction in health budget-profitability of a generic: how to be competitive
- Workshop on Ophthalmic Formulations, 2012, Italy
:Nanotechnologies in ophthalmic drug delivery-regulatory affairs and marketign aspects
- Generics&Biosimilars Summit 2012, Spain
: Innovation in generic medicine: complex, difficult to make generics
Á¤ºÎÀç ±âÀÚ boojae@geniepark.co.kr
<ÀúÀÛ±ÇÀÚ © Á¦´ÏÆÄÅ©, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>